Posted by Michael Wonder on 31 Jan 2023
Jazz Pharmaceuticals receives NICE recommendation for the reimbursement of Epidyolex (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex in England
31 January 2023 - Jazz Pharmaceuticals today announced that Epidyolex (cannabidiol 100 mg/mL oral solution), developed by GW Pharmaceuticals, has been recommended for reimbursement by NICE for adjunctive therapy of seizures associated with tuberous sclerosis complex for patients two years of age and old.
Following earlier decisions by the Scottish Medicines Consortium, Northern Ireland's Strategic Planning and Performance Group and the All Wales Medicines Strategy Group this recommendation now ensures all eligible UK patients who may benefit from this medicine will be able to receive reimbursed access to Epidyolex from 1 March 2023.
